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Abstract
Peripheral sensory diabetic neuropathy is characterized by morphological, electrophysiological and
neurochemical changes to a subpopulation of primary afferent neurons. Here, we utilized a
transgenic mouse model of diabetes (OVE26) and age-matched controls to histologically examine
the effect of chronic hyperglycemia on the activity or abundance of the enzymes acid phosphatase,
cytochrome oxidase and NADPH-diaphorase in primary sensory neuron perikarya and the dorsal
horn of the spinal cord. Quantitative densitometric characterization of enzyme reaction product
revealed significant differences between diabetic, compared to control, animals for all three
enzymes. Levels of acid phosphatase reaction product were found to be significantly reduced in
both small diameter primary sensory somata and the dorsal horn. Cytochrome oxidase activity was
found to be significantly lower in small primary sensory somata while NADPH-diaphorase labeling
was found to be significantly higher in small primary sensory somata and significantly lower in the
dorsal horn. In addition to these observed biochemical changes, ratiometric analysis of the number
of small versus large diameter primary sensory perikarya in diabetic and control animals
demonstrated a quantifiable decrease in the number of small diameter cells in the spinal ganglia of
diabetic mice. These results suggest that the OVE26 model of diabetes mellitus produces an
identifiable disturbance in specific metabolic pathways of select cells in the sensory nervous system
and that this dysfunction may reflect the progression of a demonstrated cell loss.
Background
Diabetic sensory neuropathies are a common, clinically
observed sequelae of hyperglycemia and are characterized
by a progressive degradation of primary afferent function
[1,2]. Functional and structural evidence suggest an early
and frequent involvement of small diameter primary sen-
sory neurons leading to nociceptive abnormalities [2-4].
In order to examine basic mechanisms underlying this
disorder, we utilized the OVE26 transgenic mouse model
of diabetes mellitus [5,6] to examine the effects of long-
standing hyperglycemia on enzyme histochemical indica-
tors of sensory neuron metabolism and evaluate the
potential utility of this model for future studies of diabetic
neuropathy. The OVE26 mouse line uses cell-specific
overexpression of calmodulin to destroy pancreatic β-cells
and the result is a viable diabetic mouse (>1 year survival)
that displays both early-onset (<1 week after birth) and
chronic elevated blood glucose (>500 mg/dl) and
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decreased serum and pancreatic insulin (<50% of normal)
[5,6]. Enzyme histochemical techniques demonstrated to
be sensitive to neuronal perturbation [7] were used to
examine the impact of long-standing hyperglycemia and
hypoinsulinemia on the distribution and activity of lyso-
somal acid β-glycerophosphatase (AP), cytochrome oxi-
dase (CO), and NADPH-diaphorase (NADPH-d; a
correlate of nitric oxide synthase in aldehyde fixed tissue
[8]) in both sensory ganglia and the spinal cord. It has
been previously demonstrated [7,11] that the metabolic
status of sensory neurons, as reflected by the endogenous
activity of specific homeostatic enzymes, is sensitive to
injury and perturbation. Therefore, these enzymes were
selected as putatively reflective of mitochondrial function
(CO), lysosomal or degradative activity (AP) and primary
sensory neuron injury or repair (NADPH-diaphorase).
The OVE26 transgenic mouse line (characterized by the
insulin promoter-linked overexpression of calmodulin in
pancreatic β-cells) used in this study displays a well-char-
acterized chronic hyperglycemia and hypoinsulinemia
within days after birth. [5,6]. Ten (five OVE26 transgenic
and five age-matched, control FVB animals) aged (>365
days old) mice were anesthetized with pentobarbital, per-
fused with 4% paraformaldehyde and the lumbar spinal
cord and sensory ganglia removed, sectioned and proc-
essed for AP, CO or NADPH-d enzyme histochemistry as
previously described [7,9-12]. Counts of primary sensory
somata were conducted on toluidine blue counterstained
sections of L5 spinal ganglia and quantified using previ-
ously published methodologies [7,12].
Quantitative analysis of CO, AP and NADPH-d staining
was undertaken on both the dorsal horn of the L5 seg-
ment of the spinal cord and the large and small cells of L5
sensory ganglion using previously described densitomet-
ric analysis [7,12]. The entire mediolateral extent of lam-
ina I to III was selected for staining intensity
measurement. Statistical analyses (t-test, Mann-Whitney
Rank Sum test, one way analysis of variance, Kruskal-Wal-
lis analysis of variance on ranks, z-test of proportions)
were conducted using SigmaStat (Jandel). Controls for
densitometric analysis consisted of: 1) simultaneous sec-
tioning and mounting of diabetic and control tissue on
the same slide to ensure identical histological processing;
2) statistical analysis to verify consistency of staining
between animals within control and experimental groups;
3) correction for small fluctuations in tissue opacity/thick-
ness by subtractive illumination whereby the density
value of white matter was subtracted from the immedi-
ately adjacent ventral horn; and 4) manual adjustment
and calibration of the video camera parameters and
microscope illumination and acquisition of all images
using identical settings. All experiments were conducted
in accordance with the guidelines of our institutions and
the National Institutes of Health regarding the care and
use of animals for experimental procedures.
Prior to fixative perfusion, the phenotypic status of
OVE26 diabetic mice were confirmed by their characteris-
tic small eyes caused by the GR19 gene in their transgenic
construct [5]. All adult OVE26 mice maintained fed blood
glucose levels of at least 400 mg/dl. At the histological
level, a survey [13] of the ratio of small (50 and 500 μm2
area) to large (500 and 1950 μm2 area) primary sensory
somata in the fifth lumbar spinal ganglia revealed a signif-
icant decrease in the proportion of small to large cells in
diabetic (1.29:1 small:large perikarya) compared to con-
trol (1.94:1 small:large perikarya) mice (P < 0.05 by z-test
of proportions; 417 cells measured). Quantitative densit-
ometric analysis of the abundance and distribution of
enzyme histochemical reaction product in dorsal root
ganglia (DRG) revealed substantive differences between
diabetic and control mice (720 cells were quantified for
both densitometry and cell size; 240 cells for each
enzyme). Small somata from the ganglia of diabetic mice
exhibited lower levels of AP (13.4% decrease; P < 0.001)
and CO (Fig 1A,B; 9% decrease; P < 0.001) reaction prod-
uct and an increase in the density of the reaction product
for NADPH-d (Fig. 1C,D; 13.2% increase; P < 0.001) in
comparison to control animals. No differences were
observed in large diameter neurons from diabetic as com-
pared to control animals.
In the spinal cord, all observed differences were confined
to lamina I to III. Motoneuron somata in the ventral horn
appeared both qualitatively and quantitatively similar in
diabetic and control animals. In diabetic animals, there
was an observable loss of AP reaction product in lamina I
and II of the dorsal horn (Fig. 2A) as compared to control
mice (Fig. 2B). Similarly, these laminae appeared to have
qualitatively fewer NADPH-d labeled fibers and neuronal
somata in diabetic (Fig. 2C) as compared to control ani-
mals. (Fig. 2D). The decrease of both AP and NADPH-d
labeling was most profound in the medial portion of lam-
ina I and II. Quantitative densitometric analysis sup-
ported the qualitative observations and revealed
significantly reduced levels of AP (P = 0.026; 27 sections
quantified) and NADPH-d (P < 0.001; 27 sections quanti-
fied) reaction product in lamina I and II of the dorsal horn
of control and diabetic mice (Table 1). No significant dif-
ferences were observed in qualitative staining appearance
or intensity of CO reaction product labeling in the dorsal
horn of diabetic, compared to non-diabetic animals (31
sections quantified).
Here we have demonstrated that chronic hyperglycemia
has an impact on both the survival and metabolic profile
of primary sensory neurons. The observed decrease in the
ratio of small to large diameter primary sensory somata inJournal of Brachial Plexus and Peripheral Nerve Injury 2007, 2:11 http://www.JBPPNI.com/content/2/1/11
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diabetic animals most likely represents a loss of unmyeli-
nated or small myelinated primary sensory neurons
although a relative increase in the number of large myeli-
nated neurons, however, unlikely, cannot be discounted.
Nonetheless, the former interpretation is supported by the
observed decrease in AP labeling in the dorsal horn of the
spinal cord. The observed decrease in AP intensity in the
surviving small neuronal somata from the DRG of the
OVE26 animals, as compared to small neurons from con-
trol DRG, suggests that acid phosphatase activity in those
Table 1: Quantitative histochemical reaction product in the dorsal horn of control and diabetic mice.
Enzyme Control Mean ± S.D. Diabetic Mean ± S.D t-test significance level
AP 6.058 ± 0.254 5.949 ± 0.210 P = 0.026*
CO 3.997 ± 0.172 3.989 ± 0.137 P = 0.800
NADPH-d 1.320 ± 0.354 0.733 ± 0.228 P < 0.001*
* indicates significant difference. Standard deviation (S.D.). Following densitometric measurements, the numbers were transformed to a 0 to 10 
scale for clarity of presentation and comparison. Optical density values fall along a range of 0 representing minimal staining intensity (no staining) 
and 10 representing extremely dense staining (black).
Enzyme histochemical reaction product in the fifth lumbar dorsal root ganglion from control and diabetic mice Figure 1
Enzyme histochemical reaction product in the fifth lumbar dorsal root ganglion from control and diabetic mice. (A,B) Cyto-
chrome oxidase reaction product in sections from control (A) and the diabetic (B) mice. Diabetic mice display reduced levels 
of CO reaction product compared to control. Quantitative analysis revealed a decrease in CO reaction product density in 
small neuronal somata. (C,D) NADPH-diaphorase reaction product in sections from control (C) and diabetic (D) mice. Dia-
betic mice display an increase in NADPH-diaphorase reaction product density compared to control. Scale bar in microns.Journal of Brachial Plexus and Peripheral Nerve Injury 2007, 2:11 http://www.JBPPNI.com/content/2/1/11
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cells is depressed. As FRAP containing sensory neurons
represent a subpopulation of unmyelinated C-fibers [14],
our results suggest that there is a loss, or at least a meta-
bolic disruption of, unmyelinated neurons in the dorsal
horn and in DRG. These results are consistent with the
possibility of apoptosis and cell loss in the DRG of rodent
models of diabetes [15,16] although differences in model,
species and duration of hyperglycemia must be consid-
ered [17,18] along with the likelihood that there are a
spectrum of different diabetic neuropathies including
painful (small fiber involvement) and non-painful (large-
fiber involvement) syndromes [2,3]. In light of this, it
should not be entirely unexpected that our observations
of a putative small fiber disorder complements findings of
large fiber disorders in alternate animal models of diabe-
tes [19].
Cytochrome oxidase is the terminal enzyme in the elec-
tron transport chain, and is therefore considered to be a
strong indicator of somatic mitochondrial activity. The
decrease in CO staining within small DRG neurons, as
compared to a similar cohort of small neurons from con-
Enzyme histochemical reaction product in the dorsal horn of the fifth lumbar spinal cord from control and diabetic mice Figure 2
Enzyme histochemical reaction product in the dorsal horn of the fifth lumbar spinal cord from control and diabetic mice. (A,B) 
Acid phosphatase reaction product in sections from control (A) and the diabetic (B) mice. Diabetic mice display reduced levels 
of AP reaction product in medial lamina I and II of the dorsal horn. (C,D) NADPH-diaphorase reaction product in lamina I and 
II of control (C) and diabetic (D) mice. A reduction in the number of labeled fibers and somata can be observed in the superfi-
cial dorsal horn of diabetic animals. Scale bar in microns and dorsal horn is to top in all sections.Journal of Brachial Plexus and Peripheral Nerve Injury 2007, 2:11 http://www.JBPPNI.com/content/2/1/11
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trol animal ganglia, suggests a disruption of oxidative
metabolism which corresponds well with results from
other animal models of diabetes that demonstrate dimin-
ished CO activity or disruptions in mitochondrial mor-
phology or function [16,20-22]. Alternatively, our
observed decrease in CO staining may reflect a simple
decrease in mitochondrial number, as DRG neurons
exposed to high glucose in vitro exposure contain fewer
mitochondria [23]. The lack of an observed change in CO
activity in the dorsal horn is not unexpected as both phys-
ical (axotomy) and functional (tetrodotoxin) disconnec-
tion have previously been shown to leave CO activity in
the dorsal horn unaltered [7].
In DRG and the dorsal horn of the spinal cord, NADPH-d
activity levels have been previously shown to be respon-
sive to peripheral neuronal injury or attenuation of elec-
trical activity [7]. Our results suggest that in addition to
the pathological state that led to our observed loss of sen-
sory neurons (and diminished NADPH-d labeling in the
dorsal horn), there is a ongoing perturbation resulting in
increased NADPH-d labeling in small DRG neurons from
hyperglycemic animals as compared to the primary sen-
sory somata from normoglycemic animals. As utilized
here, NADPH-d enzyme histochemical reaction product
represents nitric oxide synthase activity [8]. The elevated
ganglionic NADPH-diaphorase and diminished CO labe-
ling in the DRG of hyperglycemic mice is consistent with
previously proposed inhibition of CO activity [24] by the
product of nitric oxide synthase, nitric oxide. Although
the reported statistically significant changes may appear to
be quantitatively modest, these percent changes represent
group averages. Qualitatively and quantitatively, the
changes are more pronounced in some animals and tis-
sues sections, and less obvious in others. This is not unex-
pected as chronic diseases processes impact individuals
with profound variability in both severity and temporal
progress.
Our results suggest that the OVE26 model of chronic
hyperglycemia does alter the overall neurochemical pro-
file of the sensory nervous system through cell loss and/or
altered enzyme activity and that this pathology seems to
specifically impact unmyelinated and/or small myeli-
nated primary sensory neurons.
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